3 min read · 24 February 2010
Luminus Devices Inc., a Billerica, Mass.-based maker of LED products for both display and illumination applications, has $19 million in sixth-round funding. Return backers includeArgonaut Private Equity, Braemar Energy Ventures, Paladin Capital Group and Stata Venture Partners. The company raised a $72 million Series E round in early 2008.
3 min read · 24 February 2010
1 min read · 24 February 2010
Ngmoco, a developer of "socially empowering games" for the iPhone, has raised $25 million in Series C funding. Institutional Venture Partners led the round, and was joined by return backers Kleiner Perkins Caufield & Byers, Norwest Venture Partners and Maples Investments. Ngmoco previously raised $15.6 million.
3 min read · 23 February 2010
3 min read · 23 February 2010
U.S. technology giant Intel Corp is planning to set up a $2 billion fund to invest in U.S. companies, the Wall Street Journal said, citing people familiar with the matter. The chipmaker, which has a unit that invests in many technology companies, is in talks with venture capital firms to seek investment ideas, the daily said.
1 min read · 23 February 2010
OrbiMed, an investment management firm focused on the healthcare sector, launched Caduceus Private Investments IV, LP, a venture capital fund, with $550 million in commitments. pproximately 80% of the new fund’s capital is from returning investors. The fund will invest primarily in venture-stage biopharmaceutical and medical device companies located in North America and Europe.
2 min read · 23 February 2010
Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr® Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System. Both products are CE marked and cleared for sale in Europe and other major international markets. The company expects that this round of financing will fund the expansion of its commercial operations through to positive cash flow and profitability.
4 min read · 23 February 2010
1 min read · 22 February 2010
Viamet Pharmaceuticals Inc., a Morrisville, N.C.-based biotech company targeting metalloenzymes, has signed a licensing option agreement with Novartis Option Fund. The deal could be worth upwards of $200 million, including an up-front payment and earnouts. Viamet previously raised around $24 million in VC funding, from Novartis Option Fund, Lilly Ventures, Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund and Astellas Venture Management.
3 min read · 22 February 2010
